Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of tanespimycin (17-N-Allylamino-17-Demethoxygeldanamycin) in patients with metastatic renal cell carcinoma; the study is reported…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• 17-N-Allylamino-17-Demethoxygeldanamycin (tanespimycin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED